Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

A measurement method includes a measurement step of measuring a first single value and a second signal value, the first signal value being based on a reaction between a first reacting substance and the sample, the second signal value being based on a reaction between a second reacting substance and the sample, the first reacting substance having a higher reactivity to a second detection target than to a first detection target, the second reacting substance having a higher reactivity to the first detection target than to the second detection target.

Disclosed herein anti-TNF therapy companion diagnostics (e.g., a predictive biomarker panel) for management of Crohn's Disease (CD). The disclosed companion diagnostics may be used to identify an appropriate treatment for a patient, and includes, for example, in vitro diagnostic tests or devices that provide information for the use of an anti-TNF therapy. The disclosed methods may be used, in certain aspects, for the identification of patients likely to respond, or as not likely to respond to an anti-TNF agent. The use of the disclosed methods may allow for dose determination, discontinuation, or the administration of combinations of therapeutic agents.

The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. Also provided is a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female.

The present invention relates to methods and apparatuses for monitoring the state of health of dairy cows, in particular of entire dairy herds. The method is based on analysing the haptoglobin (HP) biomarker and part of the polymeric immunoglobulin receptor (PIGR), the secretory component (Secretory Component, SC), in a milk sample. In particular, the claimed method and apparatus of the invention make it possible to diagnose mastitis or systemic diseases which occur outside the udder on the basis of the protein biomarker described here. The invention therefore makes it possible to regularly monitor the general state of health of a dairy herd. The present invention relates to non-invasive diagnostic methods and to apparatuses and diagnostic kits for carrying out these methods.

The present invention relates to methods for predicting a risk of a subject for Type 1 diabetes (T1D) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods.

Identifying in the presence of an SARS-CoV-2, infection of COVID-19 in a human subject and/or for classifying the risk of such infection progressing to a severe or critical disease, using a system functionally associated with at least one analyzer for analyzing the blood sample, is disclosed. The system includes at least one of an input interface or a transceiver, and one or more processors functionally associated therewith. A storage medium associated with the processor(s) has stored instructions to receive biographical information relating to the human subject, and instructions to receive measurements of a plurality of serum biomarkers. Further stored are instructions to apply a neural network algorithm to the measurements of the plurality of biomarkers and the biographical information, and instructions to identify, based on an output of the neural network algorithm, a COVID-19 infection or to classify the risk of such infection progressing to a severe or critical disease.

Identifying and classifying a liver condition in a human subject based on a blood sample obtained from the human subject in a system being functionally associated with at least one analyzer for analyzing the blood sample is disclosed. The system includes at least one of an input interface or a transceiver, one or more processors, and a computer readable storage medium for instructions execution by the processor(s). The storage medium has stored instructions to receive biographical information relating to the human subject, and instructions to receive, from the analyzer(s), measurements of a plurality of serum biomarkers. The storage medium further has stored instructions to apply a neural network algorithm to the received measurements and biographical information, and instructions to identify, based on an output of the neural network algorithm, the presence of a liver condition, and to classify a severity of the liver condition.

An assay method for detecting the presence or amounts of VCAM-1 and A2M in a sample using fluorescence resonance energy transfer (FRET).

The invention provides gastroenterological cancer determination methods that involve contacting a specimen, an antibody 1 that recognizes an chain of human haptoglobin, and an antibody 2 that recognizes a chain of human haptoglobin and does not recognize human haptoglobin in which an SS bond is cleaved to form a complex 1, or contacting the specimen and two antibodies selected from the antibodies 2 that recognize a chain of human haptoglobin and do not recognize human haptoglobin in which an SS bond is cleaved to form a complex 2. A determination is made based on the measurement of complex 1 or 2. Alternatively, the specimen and two antibodies selected from the antibodies 1 that recognize an chain of human haptoglobin are contacted to form a complex 3, and a determination is made by comparing the measurement results of complex 1 or 2 with complex 3.